3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
2
Phase 1
2
Phase NA
1
Phase 2/3
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
9
Small Cell Lung Carcinoma
7
Biliary Tract Neoplasms
7
Carcinoma, Hepatocellular
6
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Carcinoma
4
Neoplasm Metastasis
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma Extensive Disease
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Non-Muscle Invasive Bladder Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Urothelial Cancer
1
Sarcoma
1
Radiation Pneumonitis
1
Pancoast Syndrome
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non Small Cell Lung Carcinoma NSCLC
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
durvalumab
×
Clear all
NCT06746116
2026-04-16
DUoENDE
AstraZeneca
Phase 3
Active not recruiting
45 enrolled
NCT04269200
2025-12-23
DUO-E
AstraZeneca
Phase 3
Active not recruiting
805 enrolled
18 charts
1 FDA